Orthopedic Spine Country Is Coming! 169 companies received admission tickets, and the price reduction is expected to start from 40%.

On September 7, the Joint Procurement Office of High-value Medical Consumables of the National Organization issued the "National Organization orthopedic Spine Consumables Centralized Procurement Document", which clearly stated that the declaration materials would be submitted by the enterprise on September 27 and the bid
would be opened on the spot.
According to the document, the centralized procurement of products for the orthopedic spine medical consumables, according to the type of surgery, surgical site, access mode and other component product systems for procurement, a total of 14 product system categories, 29 bidding units, 872 sets of systems, the country's 6426 medical institutions to fill in the procurement demand of 1.
2084 million sets (excluding bone cement), involving a total of 169 declaring enterprises, including foreign-funded leaders Johnson & Johnson, Medtronic, domestic head enterprises Weigao Orthopedics, Sanyou Medical, Beijing Fuller, Tianjin Zhengtian, Dabo Medical and other enterprises
.
Compared with the 2-year procurement cycle of artificial joints, the procurement cycle of the spine national procurement is set at 3 years, calculated from the actual implementation date of the selection results, and the first year of the agreed procurement volume is implemented
from January to February 2023.
Provinces that have carried out centralized procurement of spinal medical consumables and are still within the purchase agreement period can postpone the implementation of the results
of this collection.
According to the comprehensive estimate of relevant data, the market size of Orthopedic consumables in China was about 19 billion yuan in 2018 and about 30 billion yuan
in 2020.
Among them, the market for joint and spine consumables is about 8.
6 billion yuan / 7.
6 billion yuan respectively, and the localization level is about
35%-40%.
Orthopedic consumables foreign brands mainly account for more than 60% of the total market share of Johnson & Johnson, Medtronic, Stryker, etc.
; The overall domestic enterprises are about 40%, and the domestic representative enterprises Weigao, iKang Medical, Dabo Medical, etc.
, the revenue growth rate is higher than that of the industry, and the market concentration has an upward trend
.
Spinal diseases are mainly divided into degenerative spine diseases, spinal trauma and tumors, and spinal deformities
.
Spinal consumables include implants and surgical consumables
.
Spinal implant consumables are mainly cervical spine, thoracolumbar spine internal fixation system (mainly nail rod or nail plate form) and intervertebral fusion device, for the treatment
of spinal degenerative diseases, spinal fractures, spinal deformities, tumors and infections and other spinal diseases.
Among them, the posterior spinal internal fixation system using pedicle screws and rods accounts for about 70%
of domestic spinal surgery.
At present, China's orthopedic implant consumables market is mainly dominated by foreign companies such as Johnson & Johnson and Medtronic occupying more than 50% of the market share
.
The business of local enterprises Weigao Orthopedics and Sanyou Medical is also mainly based on
spinal consumables.
Among them, Weigao orthopedic spine products will account for nearly half of the main business income in 2021, and Sanyou Medical's spine products will account for 87%
of the operating income.
In terms of local collection, in July 2019, Anhui Province took the lead in piloting the collection of spinal consumables, with an average price reduction of 55.
9% for domestic products, an average price reduction of 40.
5% for imported products, an overall average price reduction of 53.
4%, and a maximum reduction of 95%
for a single component.
In July 2021, Anhui once again carried out the second round of collection and mining of orthopedic spine consumables, and the highest price reduction of the selected price reached 82.
88%, and the average decrease was 54.
6%.

At that time, according to Li Yu, director of the Anhui Provincial Pharmaceutical Centralized Procurement Center, a set of high-end products of a domestic mainstream brand clinical surgical thoracolumbar posterior nail rod, in 2019, the price of the selected one set was about 6380 yuan, and after the re-collection bidding in 2021, the price of the proposed 1 set was reduced to about 2711 yuan, and the price was reduced by about 57.
5%; A set of cervical anterior fixation fusion device, in 2019, the price of the selected one set was about 5215 yuan, and then it was reduced to 2215 yuan, a decrease of about 57.
5%.

It can be seen that the spinal national mining of the price limit of each product can be called loose, according to the "Science and Technology Innovation Board Daily" report, "this limit price is OK for domestic brands, compared to Anhui is not bad.
"
However, since enterprises will face fierce competition in the bidding process, the actual quotation is expected to be much lower than the limit price
.
At the same time, according to the rules of the proposed bid, the Financial Associated Press reported that the industry expects the reduction to be at least more than
40% of the limit price.
Procurement of disease oncology pharmaceutical enterprises